Key Points
- CEO Stephen Gunstream purchased 26,000 shares on March 6 at $2.15 each for a total of $55,900, raising his holding to 269,497 shares (a 10.68% increase), as disclosed in an SEC filing.
- Alpha Teknova reported ($0.09) EPS and $9.98M revenue for the quarter (revenue slightly above estimates) but remains unprofitable with negative margins and ROE; analysts' consensus is a Hold rating with an average price target of $8.00.
Alpha Teknova, Inc. (NASDAQ:TKNO - Get Free Report) CEO Stephen Gunstream bought 26,000 shares of the stock in a transaction on Friday, March 6th. The shares were bought at an average price of $2.15 per share, for a total transaction of $55,900.00. Following the completion of the transaction, the chief executive officer directly owned 269,497 shares of the company's stock, valued at $579,418.55. This trade represents a 10.68% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Alpha Teknova Trading Up 0.5%
Shares of Alpha Teknova stock opened at $2.12 on Tuesday. The company has a 50-day moving average of $2.87 and a two-hundred day moving average of $4.14. Alpha Teknova, Inc. has a 12-month low of $1.91 and a 12-month high of $7.48. The company has a current ratio of 4.58, a quick ratio of 3.64 and a debt-to-equity ratio of 0.19. The stock has a market cap of $113.61 million, a PE ratio of -6.42 and a beta of 0.39.
Alpha Teknova (NASDAQ:TKNO - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). The business had revenue of $9.98 million for the quarter, compared to analyst estimates of $9.62 million. Alpha Teknova had a negative return on equity of 23.32% and a negative net margin of 42.59%. On average, research analysts anticipate that Alpha Teknova, Inc. will post -0.58 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have recently weighed in on TKNO. Weiss Ratings restated a "sell (d-)" rating on shares of Alpha Teknova in a research report on Wednesday, January 21st. Zacks Research raised shares of Alpha Teknova to a "hold" rating in a research note on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $8.00.
Get Our Latest Stock Report on TKNO
Institutional Investors Weigh In On Alpha Teknova
Institutional investors and hedge funds have recently bought and sold shares of the stock. Tradewinds LLC. purchased a new stake in shares of Alpha Teknova in the third quarter valued at $969,000. Roubaix Capital LLC increased its position in Alpha Teknova by 89.5% during the 3rd quarter. Roubaix Capital LLC now owns 833,819 shares of the company's stock worth $5,161,000 after purchasing an additional 393,881 shares in the last quarter. Royce & Associates LP purchased a new stake in Alpha Teknova during the 4th quarter worth about $1,116,000. ProShare Advisors LLC acquired a new position in Alpha Teknova in the 4th quarter valued at about $38,000. Finally, Conestoga Capital Advisors LLC lifted its holdings in Alpha Teknova by 2.6% in the 4th quarter. Conestoga Capital Advisors LLC now owns 317,084 shares of the company's stock valued at $1,205,000 after purchasing an additional 8,145 shares in the last quarter. Hedge funds and other institutional investors own 13.81% of the company's stock.
Alpha Teknova Company Profile
(
Get Free Report)
Alpha Teknova, Inc (NASDAQ: TKNO) is a life science tools and reagents company that develops, manufactures and distributes proprietary products to support research, drug discovery and biomanufacturing. Its offerings target academic institutions, pharmaceutical and biotechnology firms, and diagnostic developers, with a focus on high-purity reagents and optimized workflows designed to accelerate molecular biology and protein science applications.
The company's portfolio includes molecular biology reagents, cell culture buffers, in vitro translation kits, custom recombinant proteins, high-throughput screening buffers and other specialized formulations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
